Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Income towards Parent Company: 2010-2018

Historic Income towards Parent Company for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$14.4 million.

  • EyePoint Pharmaceuticals' Income towards Parent Company fell 139.24% to -$14.4 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$34.6 million, marking a year-over-year decrease of 99.88%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.64% down from last year.
  • According to the latest figures from Q3 2018, EyePoint Pharmaceuticals' Income towards Parent Company is -$14.4 million, which was down 46.89% from -$9.8 million recorded in Q2 2018.
  • In the past 5 years, EyePoint Pharmaceuticals' Income towards Parent Company registered a high of $20.6 million during Q3 2014, and its lowest value of -$14.4 million during Q3 2018.
  • For the 3-year period, EyePoint Pharmaceuticals' Income towards Parent Company averaged around -$6.4 million, with its median value being -$6.0 million (2017).
  • In the last 5 years, EyePoint Pharmaceuticals' Income towards Parent Company soared by 657.80% in 2014 and then tumbled by 8,568.66% in 2017.
  • Over the past 5 years, EyePoint Pharmaceuticals' Income towards Parent Company (Quarterly) stood at -$4.1 million in 2014, then dropped by 27.26% to -$5.2 million in 2015, then skyrocketed by 98.71% to -$67,000 in 2016, then crashed by 8,568.66% to -$5.8 million in 2017, then tumbled by 139.24% to -$14.4 million in 2018.
  • Its last three reported values are -$14.4 million in Q3 2018, -$9.8 million for Q2 2018, and -$4.7 million during Q1 2018.